Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Myeloid 1Lymphoid 1Genitourinary 1Gastrointestinal 1CNS 1

Conditions

Sarcoma 78Osteosarcoma 34Melanoma 22Sarcoma, Ewing 20Neuroblastoma 19Rhabdomyosarcoma 17Ovarian Neoplasms 17Gastrointestinal Stromal Tumors 17Colorectal Neoplasms 16Glioblastoma 15Bone Neoplasms 15Sarcoma, Kaposi 14Rhabdoid Tumor 14Neoplasms 14Breast Neoplasms 14Wilms Tumor 13Liposarcoma 13Neoplasm Metastasis 12Gliosarcoma 12Medulloblastoma 11Lymphoma, Non-Hodgkin 11Hepatoblastoma 11Glioma 11Carcinoma, Non-Small-Cell Lung 11Stomach Neoplasms 10Neurofibrosarcoma 10Thyroid Neoplasms 9Recurrence 9Pancreatic Neoplasms 9Ependymoma 9

Interventions

ulixertinib 1tipifarnib 1tazemetostat 1selpercatinib 1palbociclib 1olaparib 1larotrectinib 1ivosidenib 1erdafitinib 1ensartinib 1X-Rays 1Vemurafenib 1Specimen Handling 1Phantoms, Imaging 1Nuclear Medicine Department, Hospital 1Magnetic Resonance Spectroscopy 1LY3023414 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Xanthogranuloma, Juvenile × Sarcoma × 30 days × Clear all
NCT03155620 2026-06-01

Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
1,377 enrolled 10 charts
CNSGastrointestinalGenitourinaryLymphoidMyeloidSarcoma

Ependymoma, Glioma, Histiocytosis, Langerhans-Cell, Lymphoma, Non-Hodgkin, Medulloblastoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Xanthogranuloma, Juvenile, Central Nervous System Neoplasms, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor, Histiocytic Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡